NAD 500 mg Dosage Guide: Injection Chart, Vial Sizes & Evidence | FormBlends

Trust Signals

• Written by the FormBlends Medical Team; reviewed against PubMed-indexed sources and USP compounding standards.
• Every major claim is evidence-graded in the ledger table below. Speculative claims are labeled as such.
• No financial relationship with any NAD+ manufacturer is disclosed. Where evidence is weak, we say so.
• Last reviewed: 2026-05-29. Sources listed at page end.

Key Takeaways

• NAD 500 mg is the most widely used single IV infusion dose in clinical practice, derived from addiction medicine protocols rather than longevity RCTs.
• A 1000 mg vial reconstituted in 10 mL sterile water yields 100 mg/mL; a 500 mg dose equals exactly 5 mL of that solution.
• Infusion rate, not total dose, drives the most common side effects (flushing, chest tightness, nausea); slowing the drip resolves them in most cases.
• Oral NAD+ precursors (NMN, NR) have more published human RCT data than parenteral NAD+ infusions for longevity endpoints.
• NAD+ is a dinucleotide coenzyme, not a peptide; grouping it with peptides is a category error that appears in marketing but not in biochemistry.

What Is NAD 500 mg and Is It the Right Starting Dose?

Table of Contents

1. Evidence Ledger: What the Research Actually Shows
2. How NAD+ Works: Mechanism With Specific Numbers
3. NAD Injection Dosage Chart by Protocol and Vial Size
4. NAD 1000 mg Vial: Reconstitution Math and Label Literacy
5. What Most Pages Get Wrong About NAD Peptide Dosage
6. Stability and Formulation: The Chemistry Behind Storage Rules
7. Honest Head-to-Head: IV NAD+ vs. Oral NMN vs. Oral NR
8. Side Effects and Rate-Dependent Reactions
9. Operational and Label Literacy: Reading a COA and Drawing a Dose
10. FAQ
11. Sources

Evidence Ledger: What the Research Actually Shows

How NAD+ Works: Mechanism With Specific Numbers

NAD+ is a dinucleotide coenzyme composed of nicotinamide and adenine joined by two phosphate groups. It serves as an electron carrier in oxidative phosphorylation and as a substrate (consumed, not just carried) for three enzyme families:

• Sirtuins (SIRT1-7): NAD+-dependent deacylases that regulate gene expression, mitochondrial biogenesis, and DNA repair. SIRT1 has a Km for NAD+ in the range of roughly 100 to 300 micromolar based on in vitro enzyme kinetics, meaning intracellular NAD+ concentrations well below the millimolar range can be rate-limiting.
• PARPs (poly-ADP-ribose polymerases): DNA damage sensors that consume NAD+ to build ADP-ribose chains. PARP1 is estimated to account for a substantial portion of NAD+ consumption during genotoxic stress, potentially depleting cellular NAD+ in minutes under heavy DNA damage loads.
• CD38/CD157: NADases expressed on immune and endothelial cells. CD38 activity increases with age and is thought to be a major driver of the age-related NAD+ decline, based on research by Camacho-Pereira et al. (2016) in mouse models.

What this mechanism does NOT prove: That raising plasma NAD+ via a 500 mg infusion translates into proportionally higher intracellular NAD+ in target tissues, or that enzyme activation in cells mirrors what is measured in blood. Plasma NAD+ and intracellular NAD+ are compartmentally distinct. The jump from "IV dose raises blood levels" to "sirtuins activated in muscle and brain" is not validated in human intervention studies.

NAD Injection Dosage Chart by Protocol and Vial Size

NAD 1000 mg Vial: Reconstitution Math and Label Literacy

Compounded NAD+ is sold in lyophilized (freeze-dried) or liquid form. Vial sizes commonly seen are 500 mg and 1000 mg. The math below applies to lyophilized powder vials; pre-mixed liquid vials use a stated concentration from the pharmacy.

Standard Reconstitution for a 1000 mg Lyophilized Vial

For IV administration, after reconstitution, the drawn volume is further diluted into 250 to 500 mL of normal saline (0.9% NaCl) before infusion. The dilution step reduces the risk of rate-related symptoms.

What Most Pages Get Wrong About NAD Peptide Dosage

1. NAD+ is not a peptide. It is a dinucleotide coenzyme. This distinction matters for regulation, pharmacokinetics, and mechanism. Peptide rules (amino acid stability, peptidase degradation) do not apply. The compound degrades through nucleotide hydrolysis, not proteolysis.

2. Dose charts are not evidence-based. Most published dose ranges originate from a small number of addiction case series, particularly work associated with the Br. Addictions clinic model, extrapolated by practitioners into wellness settings. There is no dose-finding RCT for parenteral NAD+ in longevity. Presenting a chart as authoritative without this caveat is misleading.

3. "NAD+ does not cross cell membranes" is the most commonly omitted fact. Exogenous NAD+ in plasma is too large and hydrophilic to enter cells directly via passive diffusion. It must be cleaved extracellularly to nicotinamide riboside (NR) or nicotinamide (Nam) and then reassembled intracellularly via the Preiss-Handler or salvage pathways. This means the downstream benefit depends on enzymatic conversion, which varies by tissue and individual.

4. Stability is underreported. Reconstituted NAD+ in solution degrades meaningfully at room temperature. Practitioners who leave vials unrefrigerated for extended periods before use may be administering a partially degraded product. See the next section.

5. Body-weight dosing is not validated. Several practitioner guides present mg/kg tables, but no published PK study has established a weight-based dosing formula for IV NAD+. These tables are practitioner estimates.

Stability and Formulation: The Chemistry Behind Storage Rules

NAD+ in aqueous solution is vulnerable to hydrolysis at the N-glycosidic bond, cleaving nicotinamide from the ADP-ribose moiety. The rate of this reaction is pH-dependent and temperature-dependent:

• pH sensitivity: NAD+ is most stable near neutral pH (approximately 6 to 7). Both acidic and alkaline conditions accelerate hydrolysis. This is why well-formulated compounded solutions buffer the product.
• Temperature sensitivity: Elevated temperature dramatically accelerates hydrolysis. Refrigeration at 2 to 8 degrees Celsius is standard for compounded vials. Reconstituted solutions should not be stored at room temperature for extended periods.
• Light sensitivity: The adenine and nicotinamide rings are photolabile. UV light exposure can degrade the compound. Amber vials or foil-wrapped packaging reduce this risk.
• Visual indicator of degradation: A solution that has shifted from clear and colorless to yellow, amber, or cloudy should be discarded. This color change reflects the accumulation of degradation products, though it is not a definitive assay.

Why this matters for the 500 mg dose: If a 500 mg vial has been stored incorrectly or used past its beyond-use date, the actual delivered dose may be substantially less than 500 mg. No simple home test can quantify remaining potency. This is an argument for sourcing from PCAB-accredited pharmacies that perform potency testing at release and assign conservative beyond-use dates.

Honest Head-to-Head: IV NAD+ vs. Oral NMN vs. Oral NR

Side Effects and Rate-Dependent Reactions

The most commonly reported side effects of NAD+ infusions are:

• Flushing: Warmth and redness, similar to niacin flush, due to prostaglandin release from nicotinamide metabolism.
• Chest tightness: Reported frequently in case series; typically benign and rate-related, but warrants clinical monitoring particularly in older or cardiovascular-compromised individuals.
• Nausea and cramping: Reduced significantly by slowing the infusion to 2 to 4 hours or longer.
• Headache and fatigue: Reported in a minority of recipients.

The standard clinical response to these reactions is to reduce the infusion rate. Pre-treatment with antihistamines is sometimes used but lacks controlled evidence for efficacy in this context. No fatalities or serious organ-level adverse events appear in the published NAD+ infusion case series, but this absence of data is not equivalent to proven safety in large populations.

Operational and Label Literacy: Reading a COA and Drawing a Dose

What a Legitimate COA for NAD 500 mg or 1000 mg Should Include

Step-by-Step Dose Draw for 500 mg from a 1000 mg Vial (100 mg/mL Concentration)

1. Confirm the pharmacy label states 100 mg/mL. If it states a different concentration, recalculate.
2. Wipe the vial stopper with 70% isopropyl alcohol. Allow to dry for 30 seconds.
3. Draw 5.0 mL into a 5 mL or 10 mL syringe with an 18-gauge drawing needle.
4. Inspect the drawn solution: clear and colorless is acceptable. Yellow, cloudy, or particulate matter: discard.
5. Inject the 5 mL into 250 to 500 mL normal saline infusion bag for IV use, or inject directly at the subcutaneous site for SQ use (dose will be smaller).
6. Label the infusion bag with patient, drug, dose, date, and time prepared.
7. Infuse IV over no less than 2 hours for 500 mg. Slower is preferred if any side effects appear.

FAQ

What is the standard NAD 500 mg dose and how is it administered?

A 500 mg dose is the most commonly prescribed single IV infusion dose in clinical practice. It is typically diluted in 250 to 500 mL normal saline and infused over 2 to 4 hours to reduce flush and chest-tightness side effects. Subcutaneous injection protocols use lower doses, usually 25 to 100 mg per injection, drawn from a 500 mg or 1000 mg vial.

How do I dose from a NAD 1000 mg vial?

A 1000 mg vial reconstituted with 10 mL sterile water gives 100 mg/mL. A 500 mg dose equals 5 mL of that solution. Always confirm the concentration with your compounding pharmacy's certificate of analysis before drawing any volume.

What does the evidence say about NAD dosing for longevity?

Human evidence is limited to small trials and mechanistic studies. No large RCT has established an optimal longevity dose. Most clinical protocols are extrapolated from addiction medicine case series (500 to 1000 mg IV) and from oral NMN or NR precursor trials, not from direct NAD+ infusion longevity RCTs.

Is subcutaneous NAD injection as effective as IV?

Direct comparative pharmacokinetic data for IV versus subcutaneous NAD+ in humans is sparse. IV delivers NAD+ immediately to plasma. Subcutaneous absorption is slower and bioavailability may differ, though some practitioners report clinical utility. This comparison has not been validated in a controlled human trial.

What is the typical NAD injection dosage chart by indication?

Addiction detox protocols: 500 to 1500 mg IV daily for 10 to 14 days (case series data). General wellness and longevity: 100 to 500 mg IV once weekly or biweekly (clinical convention, not RCT-derived). Subcutaneous maintenance: 25 to 100 mg daily or every other day. These ranges reflect practice patterns, not proven optimal doses.

How should a NAD 500 mg vial be reconstituted and stored?

Reconstitute with sterile bacteriostatic water per the pharmacy label. Refrigerate at 2 to 8 degrees Celsius. Use within the pharmacy's beyond-use date. Protect from light. Discard if the solution turns yellow-brown or becomes cloudy.

What side effects are associated with NAD 500 mg infusions?

The most common are flushing, nausea, chest tightness, and cramping. These are directly related to infusion rate. Slowing the drip typically resolves them. Serious adverse events are rare in published case series, but large controlled safety trials do not exist.

How does NAD+ compare to oral NMN or NR supplementation?

Oral NMN and NR have more human RCT data than parenteral NAD+ infusions. IV NAD+ achieves higher acute plasma peaks but carries more cost and inconvenience and has no proven superiority for long-term longevity endpoints. Oral precursors are the evidence-heavier choice for most people.

Is NAD+ a peptide?

No. NAD+ is a dinucleotide coenzyme, not a peptide. It is sometimes grouped with peptide-adjacent longevity compounds in clinical and marketing contexts, which is a category error. Its regulatory and pharmacokinetic profile differs substantially from amino-acid-based peptides.

Can NAD dosage be adjusted based on body weight?

No validated weight-based dosing formula exists for NAD+ infusions in humans. Published addiction medicine protocols used flat doses of 500 to 1000 mg. Weight-based adjustments are applied empirically by some practitioners but are not derived from pharmacokinetic dose-finding studies.

What should I look for on a NAD vial COA?

Check: stated concentration, identity confirmation by HPLC or mass spectrometry, purity above 98%, sterility per USP 71, endotoxin testing per USP 85, beyond-use date with stability backing, and verifiable pharmacy accreditation. Absence of endotoxin data is the most important red flag for injectable products.

Does NAD degrade in solution and how fast?

Yes. NAD+ in aqueous solution undergoes hydrolysis, accelerated by heat, light, and non-neutral pH. The rate depends on formulation specifics. Refrigeration and light protection significantly slow degradation. This is why compounded vials carry beyond-use dates that are often 30 to 90 days, not indefinite.